Implementation of carotid artery ultrasound imaging algorithm based on multicore DSP

超声成像在医学影像诊断中有着广泛的应用,传统的医学超声成像设备体积大、功耗高,便携性及网络传输性都有一定的限制。对常用的超声成像原理及算法进行分析及仿真,在超声成像前端、中端、后端3个处理阶段中,重点介绍中端处理方法,并将常用的人体组织及血流信息超声成像算法移植到在TMS320C6472多核DSP上,实现了人体颈动脉样本数据的成像。Ultrasound imaging is widely used in the medical imaging diagnosis. The portability and network transport properties of the traditional medical ultrasound imaging equipment has limited due to its large size and high power consumption. The common ultrasound imaging principles and algorithms were analyzed and simulated. There are three stages:front-end,middleend and back-end in ultrasound imaging processing. This paper highlights the processing method at middle-end. The popular ultrasound imaging algorithm for human tissue and blood flow information was transplanted to the TMS320C6472 multicore DSP,by which the human carotid ultrasound imaging was realized.2014年厦门大学大学生创业创新训练计划专项经费支持(2014Y0598

浅论我国大黄鱼产业转型升级之对策

经过30多年的研究与发展,我国大黄鱼产业已进入转型升级阶段。本文就加快大黄鱼原良种体系建设、规范养殖网箱布局和优化网箱结构、提高养殖经济效益与产品质量、加快全价人工配合饲料研发与推广应用、实施鱼病综合防控技术、提高产品加工率、实施品牌战略、进一步发挥行业协会作用、发掘大黄鱼文化等方面,论述了我国大黄鱼产业转型升级的对策。福建省科技重大专项专题(2016NZ0001-4);;中央引导地方科技发展专项(2017L3019);;现代农业产业技术体系专项资金(CARS-47);;福建省自然科学基金(2015J06019

南海张裂过程及其对晚中生代以来东南亚构造的启示——IODP建议书735-Full介绍

南海的形成揭示了大陆边缘张裂和盆地形成的复杂模式，尽管已经进行了广泛研究，但是关于基底岩石和深海盆沉积层的精确年代数据还很缺乏，这使得对南海张裂年代的估计存在很大的误差，对张裂机制和历史的各种假设没有得到验证。同时只有对南海的张裂过程有了精确地分析与刻画，才能更好地理解西太平洋边缘海盆地的形成以及它们在印支块体受印度－欧亚板块碰撞而向东南挤出、青藏高原隆升中可能起到的作用。2009年正式提交的国际综合大洋钻探计划（IODP）建议书735－Full建议在南海深海盆内的4个站位上实施钻探。这4个站位分布在南海盆地4个不同的次级构造单元上（南海东北部、西北次海盆、东部次海盆和西南次海盆），这样的站位设计会确保完成本建议书的整体研究目标，即揭示南海的张裂历史和它对晚中生代以来东南亚构造的启示。位于南海盆地最东北部的站位有助于确定该区域地壳的属性和验证古南海是否存在，位于西北次海盆的站位可能会提供南海的最早张裂年代，另外2个分别位于东部次海盆和西南次海盆的站位将重点确定2个次海盆的绝对年龄、基底矿物成分与磁化率以及2个次海盆的相对张裂次序。这些站位的水深大约在2910～4400m，钻探深度预计到海底以下大约700～2200m，总的钻透深度为5959m，其中5359m穿透沉积层，另外600m或400m钻入基底。所有这些站位的位置是由已有的地球物理观测数据所确定，目前计划收集更多的地质与地球物理数据以满足IODP对井位调查数据的要求

地下水埋深对塔里木河下游建群种植物叶片δ~(13)C值的影响[J]

通过对塔里木河下游不同地下水埋深梯度下胡杨和柽柳叶片δ13 C值的测定,分析了地下水埋深变化对胡杨和柽柳的长期水分利用效率的影响,为塔里木河下游退化生态系统植被保育和恢复提供科学依据。研究结果表明,随着地下水埋深从2.4m增加到9.1m,胡杨叶片δ13 C值呈现出先升后降的趋势,且在9.1m处胡杨很可能是通过减少地上生物量的方式来适应加剧的干旱;而柽柳叶片δ13 C值则随着地下水埋深的增加而逐渐增加,其水分利用效率不断增加,且对地下水埋深变化的适应宽度也较大。对比同一地下水埋深下胡杨和柽柳叶片的δ13 C值发现,随着地下水埋深不断增加,胡杨的抗旱性比柽柳的弱;对比不同地下水埋深的植物叶片的δ1..

黑河下游不同林龄胡杨水分来源的D、18O同位素示踪/Application of D and 18O stable isotopes in analyzing the water sources of different ages of Populus euphratica in the lower reaches of the Hei River[J]

对黑河下游不同林龄胡杨木质部水及其不同潜在水源稳定同位素组成(δD、δ18O)的测定分析,探讨不同潜在水源对胡杨的贡献.结果表明:(1)不同林龄胡杨木质部δ18O差异显著,胡杨幼苗、成熟木、过熟木的δ18O值分别为-5.368 14‰、-6.032 75‰和-6.924 18‰;(2)不同林龄胡杨所利用的水分来源不同,胡杨幼苗主要利用30～50 cm的土壤水,利用率在70％左右,对地下水的利用仅为6％;成熟木主要利用200～220 cm的土壤水及地下水,对地下水的利用最多达85％;胡杨过熟木主要利用100～260 cm的土壤水及地下水,深度范围较幼苗和成熟木都广,对地下水的利用较高,最多达96％,胡杨成熟木和过熟木主要利用的是地下水

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials